Abstract Search

ea0056p861 | Pituitary - Clinical | ECE2018

An open-label, multicentre, single-arm, expanded-access study of subcutaneous (s.c.) pasireotide in patients with Cushing’s disease (CD)

Fleseriu Maria , Iweha Chioma , Salgado Luiz , Mazzuco Tania Longo , Patino Heather , Campigotto Federico , Maamari Ricardo , Limumpornpetch Padiporn

Introduction: Pasireotide sc has a proven favourable efficacy and safety profile in CD patients, as shown in clinical trials. Here, we report safety and efficacy results from an expanded-access study designed to allow CD patients to receive pasireotide until regulatory approval for commercial use and reimbursement was obtained in their country.Methods: Pasireotide-naïve adults with CD (mean 24-hour urinary free cortisol [mUFC; of three samples] exce...

0 shares

ea0049gp187 | Pituitary & endocrine Tumours | ECE2017

Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing’s disease (CAPACITY)

Pivonello Rosario , Kadioglu Pritam , Bex Marie , Devia Deyanira Gonzalez , Boguszewski Cesar , Yavuz Dilek Gogas , Patino Heather , Campigotto Federico , Pedroncelli Alberto , Fleseriu Maria , Biller Beverly M K , Feelders Richard

Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushings disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...

0 shares

Endocrine Abstracts

An open-label, multicentre, single-arm, expanded-access study of subcutaneous (s.c.) pasireotide in patients with Cushing’s disease (CD)

Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing’s disease (CAPACITY)

BiosciAbstracts